[{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Zidesamtinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : The net proceeds will be used to fund the clinical development of NVL-520 (zidesamtinib), which is being evaluated in early-stage clinical studies for the treatment of non-small cell lung cancer.

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 16, 2024

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : J.P. Morgan

                          Deal Size : $500.0 million

                          Deal Type : Public Offering

                          blank

                          02

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : The net proceeds will be used to fund the clinical development of NVL-520 (zidesamtinib), which is being evaluated in early-stage clinical studies for the treatment of non-small cell lung cancer.

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 16, 2024

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : J.P. Morgan

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank

                          03

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : NVL-520 (zidesamtinib) is a novel brain-penetrant ROS1-selective tyrosine kinase inhibitor. It is being evaluated for ROS1-positive metastatic non-small cell lung cancer.

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 27, 2024

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : The net proceeds will fund clinical development and research of current or additional pipeline candidates including NVL-520, a ROS1-selective tyrosine kinase inhibitor, NVL-655, an ALK-selective inhibitor, and NVL-330, a HER2-selective tyrosine kinase in...

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 16, 2023

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : J.P. Morgan

                          Deal Size : $300.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : NVL-520 is a brain-penetrant ROS1-selective inhibitor designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with the prevalent G2032R resistance mutation and those with the S1986Y/F, L...

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 09, 2023

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : NVL-520 is a novel brain-penetrant ROS1-selective inhibitor designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with the prevalent G2032R resistance mutation.

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 13, 2022

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Nuvalent intend to use the net proceeds, to fund research and clinical development of current or additional pipeline candidates including NVL-520, NVL-655 and NVL-330, and for working capital and other general corporate purposes.

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 31, 2022

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : J.P. Morgan

                          Deal Size : $230.0 million

                          Deal Type : Public Offering

                          blank

                          08

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : NVL-520 is novel brain-penetrant ROS1-selective inhibitor created with the aim to simultaneously overcome the clinical challenges of emergent treatment resistance, off-target CNS adverse events, and brain metastases that may limit the use of currently av...

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 28, 2022

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : NVL-520 is brain-penetrant ROS1-selective inhibitor designed to remain active in tumors that have developed resistance to available ROS1 inhibitors, including tumors with prevalent G2032R resistance mutation and those with S1986Y/F, L2026M, or D2033N res...

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 09, 2022

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : NVL-520 and NVL-655 have been designed to address the clinical challenges of emergent treatment resistance, off-target CNS adverse events, and brain metastases that may limit the use of currently available ROS1 and ALK kinase inhibitors.

                          Product Name : NVL-520

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 21, 2022

                          Lead Product(s) : Zidesamtinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank